Magenta Therapeutics Inc MGTA:NASDAQ

Last Price$1.30NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/24/22

Today's Change0(0.00%)
Bid (Size)$1.26 (12)
Ask (Size)$1.29 (9)
Day Low / HighN/A - N/A
Volume3.3 M
 

View Biotechnology IndustryPeer Comparison as of 06/24/2022

 

Magenta Therapeutics Inc ( NASDAQ )

Price: $1.30
Change: -0.12 (8.45%)
Volume: 3.3 M
4:00PM ET 6/24/2022
 
 

Galectin Therapeutics Inc ( NASDAQ )

Price: $1.26
Change: +0.01 (0.80%)
Volume: 95.6 K
4:00PM ET 6/24/2022
 
 

Synlogic Inc ( NASDAQ )

Price: $1.13
Change: -0.02 (1.74%)
Volume: 151.8 K
4:00PM ET 6/24/2022
 
 

aTyr Pharma Inc ( NASDAQ )

Price: $2.86
Change: -0.03 (1.04%)
Volume: 89.4 K
4:00PM ET 6/24/2022
 
 

Cortexyme Inc ( NASDAQ )

Price: $2.27
Change: -0.10 (4.22%)
Volume: 3.9 M
4:00PM ET 6/24/2022
 

Read more news Recent News

Goldman Sachs Adjusts Price Target for Magenta Therapeutics to $2 From $3, Keeps Buy Rating
11:31AM ET 5/24/2022 MT Newswires

Magenta Therapeutics (MGTA) has an average buy rating among analysts, with a price target range of $2 to $20. (MT Newswires covers equity, commodity and...

Wedbush Adjusts Magenta Therapeutics Price Target to $6 From $7, Maintains Outperform Rating
12:51PM ET 5/16/2022 MT Newswires

Magenta Therapeutics (MGTA) has an average rating of Buy and price targets ranging from $6 to $8, according to analysts polled by Capital IQ. (MT Newswires...

Magenta Therapeutics Shares Drop After Slew of Target Cuts
1:32PM ET 4/18/2022 MT Newswires

Magenta Therapeutics (MGTA) shares were down almost 10% on Monday afternoon after a series of price-target cuts. Mizuho Securities cut the price target to...

Mizuho Securities Adjusts Magenta Therapeutics' Price Target to $8 From $17, Reiterates Buy Rating
7:34AM ET 4/18/2022 MT Newswires

Magenta Therapeutics (MGTA) has an average rating of buy and price targets ranging from $6 to $8, according to analysts polled by Capital IQ. (MT Newswires...

Company Profile

Business DescriptionMagenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers patient preparation, stem cell collection, cell dose, and safe immune regeneration programs. Its platform include autologous and allogeneic transplant, and gene therapy. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 2015 and is headquartered in Cambridge, MA. View company web site for more details
Address100 Technology Square
Cambridge, Massachusetts 02139
Phone+1.857.242.0170
Number of EmployeesN/A
Recent SEC Filing06/06/20224
President, Chief Executive Officer & DirectorJason Gardner
COO, CFO, Treasurer & Chief Accounting OfficerStephen Frank Mahoney
Chief Scientific Officer & Head-ResearchLisa M. Olson
Chief Technical OfficerDavid Nichols

Company Highlights

Price Open$1.44
Previous Close$1.42
52 Week Range$0.92 - 10.84
Market Capitalization$76.4 M
Shares Outstanding58.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.33
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-42.77%

Analyst Ratings as of 01/05/2022

Buy
6
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset